http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-508390-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c275038cf36535d44a526cb28203c03d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4741 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-153 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2000-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddbe392a7dff95a847c466ded39e9a04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61244674fbd634e1a8342feb6580b7b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_504b232835f87da3a697e7bd9f2a295b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eea873fe670468ba4ff2d96cba7c0b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_956e8d30b2876dce0411f51510779c26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e505d7b6bc38fcf2ccb73e33c6988bab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19949fd3ed6326cc004add4cc8d0df1d |
| publicationDate | 2001-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-508390-A |
| titleOfInvention | New dihydrofuro[3,4-b]quinolin-1-one compounds, cyclopenta[b]-quinolinone compounds, thieno[3,4-b]quinolinone compounds, and acridinone compounds; a process for their preparation and pharmaceutical compositions containing them |
| abstract | There is disclosed: a compound of formula (I), a method of preparation for this compound and pharmaceutical compositions thereof, wherein: ---- represents a single bond or no bond R0 represents H, hydroxy group, or a linear or branched (C1-C6) alkoxy group; R1 and R2, which are identical or different, each represents: hydrogen, halogen, linear or branched (C1-C6) alkyl group, linear or branched (C1-C6) alkoxy group, hydroxy group, linear or branched (C1-C6) polyhaloalkyl group, nitro group, amino group optionally substituted by one or two linear or branched (C1-C6) alkyl groups, group of formula (II) wherein m represents an integer from 1 to 4, or R1 and R2 form together with the carbon atoms carrying them an aromatic or non-aromatic mono- or bi-cyclic group having from 5-12 ring members and optionally containing 1 or 2 heteroatoms selected from O, S and N; R3 represents H or a group of formula R4 wherein R4 represents: - an aryl group, - a heteroaryl group, - a (C3-C8) cycloalkyl group, - a linear or branched (C1-C6) alkyl group optionally substituted by an aryl group, by a heteroaryl group, by a hydroxy group, by a linear or branched (C1-C6) alkoxy group, or by a group of formula NR5R6 wherein R5 and R6 (which are identical or different) each represents a linear or branched (C1-C6) alkyl group or a linear or branched (C1-C6) hydroxyalkyl group, or R5 and R6 form together with the nitrogen atom carrying them a nitrogen heterocycle,- a group of formula COR7, wherein R7 represents one of the following groups: o aryl, o linear or branched (C1-C6) alkyl (optionally substituted by a group of formula NR8R9 wherein R8 and R9, which are identical or different, each represents a linear or branched (C1-C6) alkyl group or a linear or branched (C1-C6) hydroxyalkyl group, or form together with the nitrogen atom carrying them a nitrogen heterocycle), o amino optionally substituted by one or more groups aryl, heteroaryl or linear or branched (C1-C6) alkyl (optionally substituted by a group of formula NR8R9), o OR10 wherein R10 represents H or an aryl group or linear or branched (C1-C6) alkyl (optionally substituted by a group of formula NR8R9), X represents O or S or a -CH2 - or -CH2-CH2- group; Ar represent an aryl, heteroaryl or aryl-(C1-C6) alkyl group in which alkyl is linear or branched; wherein aryl is phenyl, biphenyl, naphthyl or tetrahydronaphthyl (each of those groups being optionally substituted as defined in the specification), heteroaryl is an aromatic mono- or bi-cyclic group having from 5-12 ring members and containing 1-3 heteroatoms selected from O, S and N (each of these heteroaryl groups being optionally substituted as defined in the specification), and nitrogen heterocycle is a saturated monocyclic group having from 5-7 ring members and containing 1-3 heteroatoms selected from O, S, and N, where one of the heteroatoms of the nitrogen heterocycle must be N; their optical isomers, hydrates, solvates and pharmaceutically acceptable addition salts thereof. |
| priorityDate | 1999-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.